T4090 vs Rhopressa for Glaucoma

Recruiting at 22 trial locations

Overseen By James H. Peace

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Laboratoires Thea

Disqualifiers: Secondary glaucoma, Advanced glaucoma, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

126 Participants Needed

Trial Summary

What is the purpose of this trial?

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

Eligibility Criteria

This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.

Inclusion Criteria

Informed consent dated and signed.

I am 18 years old or older.

I have been diagnosed with glaucoma or high eye pressure in both eyes.

Exclusion Criteria

I have a specific type of glaucoma not caused by an eye injury.

My glaucoma is in an advanced stage.

I have not had eye trauma, infection, or significant inflammation in the last 6 months.

Treatment Details

Interventions

• Rhopressa®
• T4090

Trial Overview The trial aims to compare the effectiveness and safety of two concentrations (0.2% and 0.3%) of T4090 ophthalmic solution against Rhopressa® in reducing eye pressure.

Participant Groups

Group I: T4090 0.3% Experimental Treatment 1 Intervention

Group II: T4090 0.2% Experimental Treatment 1 Intervention

Group III: Rhopressa® Active Control 1 Intervention

Who Is Running the Clinical Trial?

Laboratoires Thea

Lead Sponsor

Trials

64

Recruited

6,900+